Latest news

Thumbnail image for Priority review for BMS’ Opdivo in liver cancer

Priority review for BMS’ Opdivo in liver cancer

US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include to include certain patients with liver cancer.

26th May 2017

Thumbnail image for Merck buys experimental tau antibody from Teijin

Merck buys experimental tau antibody from Teijin

Merck & Co has bought itself an exclusive global licence from Teijin Pharma to develop, manufacture and commercialise an investigational preclinical antibody candidate targeting a protein called tau.

26th May 2017

Thumbnail image for EU regulators widen approval for Zebinix

EU regulators widen approval for Zebinix

The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.

25th May 2017

Thumbnail image for UK biotech takes pole position in Europe

UK biotech takes pole position in Europe

The UK has the strongest and most robust clinical pipeline in Europe, with the number of drug products in development higher in the UK than anywhere else in the region, according to a new report by the BioIndustry Association.

25th May 2017

Thumbnail image for GW Pharma poised to file Epidiolex in the US

GW Pharma poised to file Epidiolex in the US

GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.

25th May 2017

Thumbnail image for US approves Keytruda for MSI-H tumours

US approves Keytruda for MSI-H tumours

The US Food and Drug Administration has cleared use of Merck & Co’s immunotherapy Keytruda to treat cancer patients identified as having a biomarker called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

24th May 2017

Thumbnail image for MSD accused of breaching UK competition law

MSD accused of breaching UK competition law

The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by MSD for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market.

24th May 2017

Thumbnail image for Full green light for Biogen’s MS drug Fampyra

Full green light for Biogen’s MS drug Fampyra

Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis.

24th May 2017

Thumbnail image for Communications Team of the Year open for entry

Communications Team of the Year open for entry

Healthcare communications continues to evolve and comprises a number of diverse, yet intrinsically linked disciplines, including medical education, PR, policy, public affairs and market access.

23rd May 2017

Thumbnail image for NHS could lose more than 2,000 GPs through Brexit

NHS could lose more than 2,000 GPs through Brexit

GP leaders are warning that nearly 3.5 million patients are at risk of losing their family doctor, if the status of doctors from the European Union is not protected during Brexit negotiations.

23rd May 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download